The role of excipients of trometamolum and meglumine in the formation of biopharmaceutical properties of medicinal products of various pharmacites release_shpascx525axbhxzcd6cm2rzfe

by ПАЛЬЧЕВСЬКА ТЕТЯНА АНДРІЇВНА, Елена Салий, Olga Baula, Константин Пальчевский, О. М. Оніщук

Published in Farmatsevtychnyi zhurnal by The State Expert Center of the Ministry of Health of Ukraine.

2021   p64-75

Abstract

At the present stage of development of the pharmaceutical industry, the use of many functional excipients (DopR), which are important components of pharmaceutical formulations, becomes relevant. DopR is one of the most influential biopharmaceutical factors on the therapeutic efficacy of drugs, increasing the therapeutic effect and safety of active pharmaceutical ingredients (APIs) through the formation of optimal compounds and appropriate dosage forms by chemical modification of the molecule responsible for pharmacological activity.
 The purpose of the work is to analyze the literature on determining the role of excipients of trometamol and meglumine as biopharmaceutical factors in drugs of different pharmacotherapeutic groups; summarize and systematize data on their impact on the bioavailability of finished drugs.
 The objects of the study are excipients trometamоlum (TНAM) and meglumine (MGA) in the composition of drugs of different pharmacotherapeutic groups. Methods of a systematic approach, bibliographic, information retrieval, generalization and analysis were used in the research.
 A systematic study of the composition of drugs of the State Register of Medicinal Products (January 2021) showed that chemically modified drugs are supplied to the pharmaceutical market not only by domestic manufacturers, but also by pharmaceutical companies from 16 countries. The general nomenclature of drugs makes 82 trade names, from them 66% – with TMM and 34% – with MGA.
 A significant number of chemically modified insoluble and sparingly soluble APIs of different pharmacotherapeutic groups indicates a significant role of TMM and IGA in the development of new effective drugs.
 Thus, organic aminoproton acceptors: trometamol and meglumine – many functional excipients that increase the activity of active molecules, their release from dosage forms, stimulate the pharmacotherapeutic effect of drugs aimed at activating the protective forces (sanogenesis) and compensatory mechanisms of the body and thus, improve the pharmacological properties of drugs, reduce the risk of adverse reactions.
In application/xml+jats format

Archived Files and Locations

application/pdf  924.0 kB
file_pwqyaqv3pffevbtxr7uepqrsve
pharmj.org.ua (publisher)
web.archive.org (webarchive)
Read Archived PDF
Preserved and Accessible
Type  article-journal
Stage   published
Date   2021-08-26
Container Metadata
Open Access Publication
In DOAJ
Not in Keepers Registry
ISSN-L:  0367-3057
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 2e32e6fa-518c-4673-bd7e-0fe9fe6b103e
API URL: JSON